Getting cytisine licensed for use world-wide: a call to action.

[1]  T. Lancaster,et al.  Nicotine receptor partial agonists for smoking cessation. , 2016, The Cochrane database of systematic reviews.

[2]  Gretchen A. Stevens,et al.  Regional contributions of six preventable risk factors to achieving the 25 × 25 non-communicable disease mortality reduction target: a modelling study. , 2015, The Lancet. Global health.

[3]  R. West,et al.  Health‐care interventions to promote and assist tobacco cessation: a review of efficacy, effectiveness and affordability for use in national guideline development , 2015, Addiction.

[4]  J. Sheridan,et al.  Pharmacokinetics of cytisine, an α4 β2 nicotinic receptor partial agonist, in healthy smokers following a single dose. , 2015, Drug testing and analysis.

[5]  Hayden McRobbie,et al.  Cytisine versus nicotine for smoking cessation. , 2014, The New England journal of medicine.

[6]  Gretchen A. Stevens,et al.  Contribution of six risk factors to achieving the 25×25 non-communicable disease mortality reduction target: a modelling study , 2014, The Lancet.

[7]  M. Stevenson,et al.  What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. , 2014, Health technology assessment.

[8]  L. Pani,et al.  Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ , 2014, Scientia pharmaceutica.

[9]  J. Stapleton.  The case for licensing cytosine now for smoking cessation is overwhelming , 2013, BMJ : British Medical Journal.

[10]  J. Prochaska,et al.  Cytisine, the world’s oldest smoking cessation aid , 2013, BMJ.

[11]  R. West,et al.  Cytisine and the failure to market and regulate for human health , 2013, Thorax.

[12]  H. McRobbie,et al.  Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis , 2013, Thorax.

[13]  R. West,et al.  Placebo-controlled trial of cytisine for smoking cessation. , 2011, The New England journal of medicine.

[14]  N. Rigotti,et al.  A survey of tobacco dependence treatment services in 36 countries. , 2009, Addiction.

[15]  W. Zatónski,et al.  Cytisine for the treatment of nicotine addiction: from a molecule to therapeutic efficacy. , 2006, Pharmacological reports : PR.

[16]  J. Etter.  Cytisine for smoking cessation: a literature review and a meta-analysis. , 2006, Archives of internal medicine.

[17]  R. Obach,et al.  METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO , 2006, Drug Metabolism and Disposition.

[18]  Brian T. O’Neill,et al.  Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation , 2005 .